 |
The Clinical
Efficacy of Using the AeroEclipse® Breath Actuated Nebulizer (BAN)
in Pulmonary Lab Testing and Implications for General Use.
YM Christensen, RRT,CPFT, CJ Flanigan,
RRT, SA Ravenscraft, M.D.,Park Nicollet Clinic, St. Louis Park, MN
Purpose: To compare the
clinical efficacy and delivery time of nebulization of beta agonist bronchodilator
with the use of the AeroEclipse® Breath Actuated Nebulizer (BAN) (Monaghan Medical
Corp.) as compared to the Airlife Misty-Neb Nebulizer (SVN) (Allegiance Healthcare
Corporation).
Methods: Adult
patients (n=40) presenting with Asthma (50%), COPD (10%) and other pulmonary
disorders (40%); receiving pre and post bronchodilator spirometry testing in
our Pulmonary Function Lab were included in the study. Each patient received
both nebulizers on two separate visits (less than 24 hours apart). Patient received
a nebulizer treatment with the BAN (n=40) 2.5mg Albuterol (0.5ml) in 0.5cc saline
run to sputter, or the SVN (n=40) 2.5mg Albuterol in 2.5cc saline (3ml unit
dose) run to sputter. FVC, FEV1, FEV1% ratio and FEF 25-75% spirometry was conducted
using the Medical Graphics 1085DX pre and 5 minutes post treatment with the
BAN and 10 minutes post treatment with the SVN.
Results: The results demonstrated
that FVC, FEV1 and FEF 25-75% for patients using the BAN were substantially
higher while FEV1% ratio favored the SVN (Table and Chart ). Importantly, total
nebulization time was reduced from 22 minutes (SVN) to 7 minutes (BAN), and
total test time was reduced from 30 minutes (SVN) to 15 minutes (BAN).
Conclusion: The administration
of 2.5mg of albuterol with the BAN produced improved results in FVC, FEV1 and
FEF 25-75%. Substantially shorter test times delivered by the BAN would allow
for more tests and associated revenue. These data support the thesis that the
BAN can reduce costs of care by delivering clinically acceptable outcomes in
significantly less time.
OF-01-206
|
|
